AOD-9604
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A modified fragment of human growth hormone marketed for fat loss, said to boost fat breakdown without raising IGF-1 or blood sugar. The mechanism is solid, but the human case is weak: its pivotal trial failed to reach significance, and cartilage-repair claims stay speculative. The FDA has flagged impurity and immune-reaction concerns in compounded batches, and most supply is unregulated research-grade product. Not FDA-approved, banned in sport under WADA.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide derived from a small section of human growth hormone. It was designed to isolate growth hormone's fat-burning properties without its muscle-building, growth-promoting, or blood sugar-raising effects. Developed in Australia in the 1990s, it completed six human clinical trials with over 900 participants but ultimately failed its main efficacy trial and drug development was halted in 2007. A sponsor announced a self-affirmed conditional food-use GRAS determination in June 2012; this was not an FDA approval.
How it works in the body
A modified fragment of human growth hormone (amino acids 176-191, with an added tyrosine at position 176) that stimulates fat breakdown (lipolysis) without affecting blood sugar or growth. It tells fat cells to release stored fat while blocking the formation of new fat. Beta-3 adrenergic signaling is implicated in animal studies, but its molecular target remains uncertain.
Research overview
AOD-9604's molecular target remains uncertain; animal studies implicate changes in beta-3 adrenergic receptor expression, stimulating fat breakdown and blocking new fat production without raising IGF-1 levels or affecting blood sugar. In animal studies, it reduced weight gain by over 50% in obese mice. An early 12-week human trial showed subjects on 1 mg/day lost 2.6 kg versus 0.8 kg on placebo. However, the larger pivotal 24-week trial with 536 obese adults failed to show statistically significant weight loss compared to placebo, which ended its development as a prescription drug. Comprehensive safety testing found no genotoxic or significant toxicity concerns. A 2015 animal study showed AOD-9604 injected into joints with hyaluronic acid improved cartilage repair in an osteoarthritis model.
Who researches AOD-9604?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data.
Anyone under 18
AbsoluteNo pediatric data.
Safety & interactions
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Children under 18
AbsoluteNo pediatric data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(11)
Rated by level of concern
Failed to demonstrate statistically significant weight loss in pivotal Phase IIb clinical trial
HighSponsor (Metabolic Pharmaceuticals) Phase 2b announcements and secondary reporting; no peer-reviewed publication of results exists. Context in Stier, Vos, Kenley. J Endocrinol Metab 2013 https://www.jofem.org/index.php/jofem/article/view/157
FDA has cited concerns about potential immunogenicity (immune reactions to the peptide)
ModerateFDA, bulk drug substances nominated for use in compounding under section 503A https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
FDA has cited concerns about peptide impurity profiles in compounded formulations
ModerateFDA 503A bulks nomination evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
Limited long-term safety data beyond 24-week trial duration
ModerateStier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Injection site irritation (subcutaneous administration)
LowExtrapolation from general SC peptide administration; route of the clinical program per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157 (no AOD-9604-specific injection-site data published)
Transient headache reported in some trial participants
LowStier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Mild flu-like symptoms reported in some trial participants
TheoreticalNo source located supporting a flu-like syndrome in AOD-9604 trials; trial adverse-event profile per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157
No data on safety during pregnancy or lactation
ModerateAbsence of published reproductive/developmental data; trial population per Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157
Quality control concerns with unregulated products sold online
HighFDA 503A bulks nomination evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)
LowMechanistic/general peptide handling; aggregation concern noted in FDA 503A evaluation https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
Prohibited in competitive sports — positive WADA test could result in sanctions
HighWADA statement on the substance AOD-9604 https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604
Interaction summary(8)
Rated by direction with this peptide
Beta-3 adrenergic receptor agonists (e.g. mirabegron)
SynergisticTheoreticalAOD-9604's lipolytic effect is abolished in beta3-AR knockout mice and it restores suppressed beta3-AR expression in obese mice, so a beta3 agonist would act on the same pathway. Entirely mechanism-derived from animal work; no human co-administration study exists, and AOD-9604 showed no fat-loss efficacy in humans, so any 'synergy' is additive only in theory.
Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749
Beta-blockers, particularly non-selective agents
CautionTheoreticalLoss-of-effect rather than a safety hazard: because the lipolytic mechanism requires an intact beta3-adrenergic pathway, adrenergic blockade would plausibly blunt any fat-mobilizing response. Note most clinical beta-blockers are beta1/beta2-selective with limited beta3 activity, and this has never been tested clinically with AOD-9604.
Mechanism inferred from beta3-AR dependence in Heffernan et al., Endocrinology 2001 https://academic.oup.com/endo/article/142/12/5182/2988749
Sympathomimetic stimulants (caffeine, ephedrine, clenbuterol, amphetamines)
CautionTheoreticalAdditive adrenergic and lipolytic stimulation is plausible in principle, but no interaction study exists and AOD-9604 itself produced no clinically significant vital-sign or ECG changes in the trial program. When AOD-9604 is used with a stimulant, cardiovascular risk derives from the stimulant, not from AOD-9604.
Mechanistic; AOD-9604 cardiovascular safety baseline from Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157
Insulin, sulfonylureas and other glucose-lowering agents
NeutralTheoreticalUnlike full-length hGH, AOD-9604 showed no adverse effect on oral glucose tolerance in randomized placebo-controlled human testing, so no anticipatory antidiabetic dose adjustment is indicated. No trial enrolled diabetic or insulin-treated patients, so this is extrapolation from a non-diabetic population; routine glucose monitoring remains sensible.
Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Recombinant human growth hormone and GH secretagogues (CJC-1295, ipamorelin, tesamorelin)
CautionTheoreticalUsing a GH fragment with agents that raise endogenous or exogenous GH reintroduces the IGF-1 elevation and glucose impairment that AOD-9604 was engineered to avoid, so the fragment's clean metabolic profile cannot be assumed to carry over. No co-administration study exists; the caution is inferred from the known effects of the co-administered agents, not from any AOD-9604 interaction data.
Contrast between fragment and full-length hGH established in Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157; no interaction study located
Intra-articular hyaluronic acid
SynergisticTheoreticalIn a single collagenase-induced rabbit knee OA model, intra-articular AOD9604 combined with hyaluronic acid outperformed either agent alone on cartilage morphology and histopathology. Animal-only, single study, intra-articular route; there is no human confirmation and no clinical use of this combination.
Kwon & Park, Ann Clin Lab Sci 2015;45(4):426-32 (rabbit model)
GLP-1 receptor agonists (semaglutide, tirzepatide)
NeutralTheoreticalMechanisms are non-overlapping (incretin/appetite signaling versus adipocyte beta3-mediated lipolysis) and no pharmacokinetic interaction is expected, but there is zero co-administration data and AOD-9604 contributed no proven weight loss of its own in Phase IIb - so it adds cost and uncertainty rather than demonstrated benefit to a GLP-1 regimen.
No published interaction data; negative AOD-9604 Phase IIb weight outcome (sponsor reporting, unpublished)
Anti-doping testing in sanctioned competition
CautionHighNot a pharmacological interaction but the highest-probability real-world harm: WADA holds AOD-9604 prohibited at all times under S0 as a non-approved substance, so use by a tested athlete risks sanction regardless of dose or route.
WADA statement on the substance AOD-9604 https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604
Known risks(11)
Failed to demonstrate statistically significant weight loss in pivotal Phase IIb clinical trial
FDA has cited concerns about potential immunogenicity (immune reactions to the peptide)
FDA has cited concerns about peptide impurity profiles in compounded formulations
Limited long-term safety data beyond 24-week trial duration
Injection site irritation (subcutaneous administration)
Transient headache reported in some trial participants
Mild flu-like symptoms reported in some trial participants
No data on safety during pregnancy or lactation
Quality control concerns with unregulated products sold online
Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)
Prohibited in competitive sports — positive WADA test could result in sanctions
Drug interactions(5)
Growth Hormone (HGH/Somatropin)
Theoretical — avoid co-administrationTheoretical additive or competitive interaction — both act on overlapping lipolytic pathways. Co-administration has not been studied and is not recommended.
Beta-3 Adrenergic Agonists (e.g., mirabegron)
Theoretical — use cautionAOD-9604 modulates beta-3-AR expression. Co-administration with beta-3 agonists could theoretically potentiate adrenergic effects.
Insulin and Oral Hypoglycemics
Low risk — monitor glucoseWhile AOD-9604 has not shown effects on glucose homeostasis in studies, patients on diabetes medications should monitor blood glucose when initiating any metabolic peptide.
Other Lipolytic Peptides (e.g., CJC-1295, Tesamorelin, GHRP-6)
Unknown — no formal studiesNo formal interaction studies exist. Using multiple lipolytic peptides together lacks evidence-based safety data.
Corticosteroids
Pharmacological antagonism — may reduce efficacyChronic corticosteroid use promotes adipogenesis and could counteract the lipolytic effects of AOD-9604.
Research & benefits
Evidence base
- Total Studies
- 20
- Human Studies
- 6
Researched for(10)
Rated by confidence in the evidence
Stimulates lipolysis (fat breakdown) in adipose tissue without affecting muscle mass
LowAnimal and cell studies show fat breakdown; human muscle mass effects remain unmeasured.
Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749; Ng et al., Horm Res 2000;53:274-8
Inhibits lipogenesis (new fat formation/de novo fatty acid synthesis)
LowReduced fat formation seen in animal and cell studies only, not tested in humans.
Ng et al., Horm Res 2000;53:274-8; Heffernan et al., Endocrinology 2001;142(12):5182-9 https://academic.oup.com/endo/article/142/12/5182/2988749
Does not elevate IGF-1 levels, unlike full-length HGH
HighConfirmed across multiple human trials measuring IGF-1 directly, with no rise versus placebo.
Stier, Vos, Kenley. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Does not impair glucose homeostasis or insulin sensitivity
HighHuman trials found no adverse effect on glucose tolerance over 24 weeks; improvement unproven.
Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Does not suppress the HPA axis
SpeculativeUntested claim, based on mechanism only; no study measured cortisol or HPA axis response.
Mechanistic inference plus general safety labs in Stier 2013 (https://www.jofem.org/index.php/jofem/article/view/157); no direct HPA-axis study located - no source directly supports this claim
Generally favorable short-term tolerability in IV and oral trials; subcutaneous safety remains unestablished
HighSix randomized human trials in about 900 subjects found tolerability similar to placebo.
Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
May support cartilage repair and regeneration (proteoglycan and collagen synthesis stimulation)
SpeculativeBased on a single small rabbit study; no human trials, mechanism unconfirmed.
Kwon & Park, Ann Clin Lab Sci 2015;45(4):426-32 (rabbit OA model)
Orally bioavailable (unlike most peptides), though subcutaneous injection is also used
LowOral dosing was used in trials, but absolute oral bioavailability was never established.
Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
No observed cardiovascular adverse events in clinical trials
MediumNo cardiovascular signal in short human trials, which were not designed for heart safety.
Stier, Vos, Kenley. J Endocrinol Metab 2013;3(1-2):7-15 https://www.jofem.org/index.php/jofem/article/view/157
Selectively targets fat metabolism without broader growth-promoting hormonal effects
LowHormonal neutrality shown in humans, but fat-targeting effect rests only on animal data.
Stier 2013 https://www.jofem.org/index.php/jofem/article/view/157 (IGF-1/glucose); Heffernan et al., Endocrinology 2001 https://academic.oup.com/endo/article/142/12/5182/2988749 (animal lipolysis)
Benefits(10)
Stimulates lipolysis (fat breakdown) in adipose tissue without affecting muscle mass
Inhibits lipogenesis (new fat formation/de novo fatty acid synthesis)
Does not elevate IGF-1 levels, unlike full-length HGH
Does not impair glucose homeostasis or insulin sensitivity
Does not suppress the HPA axis
Favorable safety profile across extensive preclinical and clinical testing (900+ participants)
May support cartilage repair and regeneration (proteoglycan and collagen synthesis stimulation)
Orally bioavailable (unlike most peptides), though subcutaneous injection is also used
No observed cardiovascular adverse events in clinical trials
Selectively targets fat metabolism without broader growth-promoting hormonal effects
Key studies(6)
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM
Endocrinology
2001
Demonstrated that AOD-9604 and HGH increase beta-3-AR RNA expression in obese mice to lean levels. Knockout mice lacked the chronic weight and lipolysis responses but retained acute energy-expenditure and fat-oxidation responses, indicating a more complex mechanism.
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R
Hormone Research
2000
Oral AOD-9604 at 500 mcg/kg/day for 19 days reduced weight gain by over 50% in obese rats with no adverse effect on insulin sensitivity.
More MI, Kenley D
Journal of Endocrinology and Metabolism
2014
Comprehensive safety review: no genotoxicity across Ames test, chromosome aberration assays. NOAEL of 100 mg/kg/day (rats, 6 months) and 50 mg/kg/day (monkeys, 9 months). Supports GRAS designation.
Kwon DR, Park GY
Annals of Clinical and Laboratory Science
2015
Combined AOD-9604 + hyaluronic acid intra-articular injection was more effective than either alone at reducing cartilage deterioration and lameness in rabbit OA model.
Misra M
Current Cardiology Reviews
2013
Comprehensive review documenting AOD-9604 Phase IIb failure: 24-week trial of 536 subjects failed to show significant weight loss. Classified AOD-9604 as a failed drug candidate.
Wilding J
Current Opinion in Investigative Drugs
2004
Review of AOD-9604 development status as of 2004, documenting Phase IIa trial progress for obesity treatment.
What research suggests over time
Weeks 2-4
Phase IIbNo significant short-term effects in published human trials.
Months 2-3
Phase IIb (negative)Phase IIb obesity trial: failed to demonstrate statistically significant weight loss vs placebo at 12 weeks.
Long-term
Phase IIb (negative)A conditional food-use GRAS determination was self-affirmed in 2012; this does not establish therapeutic approval or fat-loss efficacy. Still sold as an unregulated product despite the negative trial result.
Regulation & availability
Why researchers look at it
Tested in over 900 people across six clinical trials with an excellent safety profile, but its pivotal 536-person Phase IIb weight loss trial failed to reach statistical significance and development was halted in 2007. A 2015 animal study showing improved cartilage repair when injected into joints has opened a potential second life for the compound. If the cartilage repair pathway advances to human trials, AOD-9604 could find the clinical niche that eluded it in obesity.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. On December 4, 2024, PCAC voted 0–12 against inclusion.
- WADA status
- Prohibited in competition and out-of-competition. Listed under WADA S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to anti-doping testing should not use AOD-9604.
- Prescribability
- AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
- Availability
- No approved pharmaceutical product was verified. Some clinics and pharmacies offer AOD-9604, but no qualifying US bulk-compounding basis was established: its nominations were withdrawn and it is absent from Category 1 and the 503A Bulks List. The food-use GRAS claim was self-affirmed in 2012, not granted by FDA in 2021. Australian approval for a cartilage-repair product has not been verified.
International status
EU
Not approved
US
AOD-9604 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
Australia
Developed at Monash University; available via compounding
Regulatory timeline(13)
- 1990sAOD-9604 developed by Metabolic Pharmaceuticals Ltd. (Melbourne, Australia) as a synthetic fragment of HGH amino acids 176-191.
- 2000Ng et al. publish preclinical metabolic studies showing 50%+ weight gain reduction in obese rats (PMID: 11146367).
- 2001Heffernan et al. publish beta-3-AR mechanism study in Endocrinology (PMID: 11713213).
- 2002Phase IIa clinical trials commence for oral AOD-9604 in obese adults.
- 2004Wilding reviews AOD-9604 development progress in Current Opinion in Investigative Drugs (PMID: 15134286).
- 2007Pivotal Phase IIb trial (24 weeks, 536 obese subjects) fails to meet primary efficacy endpoint of statistically significant weight loss.
- 2007-02-21Metabolic Pharmaceuticals Ltd. terminates AOD-9604 drug development program.
- 2014More & Kenley publish comprehensive safety/metabolism review supporting nutraceutical use (DOI: 10.14740/jem213w).
- 2015Kwon & Park publish cartilage repair study in rabbit OA model, showing efficacy with hyaluronic acid (PMID: 26275694).
- 2012-06-25Calzada announces a self-affirmed conditional food-use GRAS determination by an expert panel. This is not an FDA-issued approval.
- 2018Widespread adoption in US compounding pharmacy and peptide therapy clinics for unapproved fat loss and joint health applications.
- 2024FDA PCAC meeting: FDA proposes NOT to include AOD-9604 on the 503A Bulks List for pharmaceutical compounding, citing immunogenicity concerns, impurity profiles, and limited long-term data.
- 2025Regulatory dispute ongoing. Compounding pharmacy advocates and clinicians challenge FDA decision. Final determination pending.
Sources & FAQs
Research sources(8)
- PubMed — Heffernan et al. (2001)
- PubMed — Ng et al. (2000)
- Journal of Endocrinology and Metabolism — More & Kenley (2014)
- PubMed — Kwon & Park (2015)
- PMC — Misra (2013), Obesity Pharmacotherapy: Current Perspectives and Future Directions
- PubMed — Wilding (2004) AOD-9604 Review
- FDA Docket — AOD-9604 Acetate (PCAC Meeting Dec 2024)
- FDA Docket — Saving AOD9604 Presentation (Edwin Lee, PCAC Dec 2024)
Frequently asked questions(6)
What is AOD-9604 and how does it differ from HGH?
AOD-9604 is a 16-amino acid synthetic peptide derived from amino acids 176-191 of human growth hormone, with an added tyrosine residue. Unlike full HGH, it selectively promotes fat metabolism without elevating IGF-1, affecting glucose levels, promoting cell growth, or causing the diabetogenic effects associated with HGH therapy.
Did AOD-9604 work in clinical trials?
It showed modest results. In a 12-week Phase IIa trial, the oral peptide produced 2.6 kg weight loss vs 0.8 kg on placebo. However, the pivotal 24-week Phase IIb trial with 536 subjects failed to meet its primary endpoint of statistically significant weight loss, and drug development was terminated in 2007.
Is AOD-9604 safe?
AOD-9604 has one of the most extensive safety dossiers of any peptide. Six clinical trials with 900+ participants showed adverse events comparable to placebo. Preclinical toxicology (6-month rat, 9-month monkey studies) found no genotoxicity or significant toxicological concerns. However, the FDA has cited concerns about long-term safety data gaps, peptide impurities, and potential immunogenicity.
Is AOD-9604 legal?
AOD-9604 is not FDA-approved. Its food-use GRAS claim came from a self-affirmed conditional determination, which does not authorize therapeutic use. Its compounding nominations were withdrawn, and it is not in Category 1 or the 503A Bulks List. WADA prohibits it at all times. Legal controls depend on jurisdiction.
Can AOD-9604 help with joint problems?
Evidence is limited to animal research. A 2015 study showed intra-articular AOD-9604 combined with hyaluronic acid reduced cartilage deterioration in a rabbit osteoarthritis model; it does not establish human benefit. A TGA-approved cartilage-repair product has not been verified.
How is AOD-9604 typically administered?
In clinical trials, AOD-9604 was given orally. In clinical practice settings, subcutaneous injection is common.